FR17C0003I1 - Steroides comme agonistes de fxr - Google Patents

Steroides comme agonistes de fxr

Info

Publication number
FR17C0003I1
FR17C0003I1 FR17C0003C FR17C0003I1 FR 17C0003 I1 FR17C0003 I1 FR 17C0003I1 FR 17C0003 C FR17C0003 C FR 17C0003C FR 17C0003 I1 FR17C0003 I1 FR 17C0003I1
Authority
FR
France
Prior art keywords
steroids
fxr agonists
compounds
formula
fxr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercept Pharmaceuticals Inc
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23050302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C0003(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of FR17C0003I1 publication Critical patent/FR17C0003I1/fr
Application granted granted Critical
Publication of FR17C0003I2 publication Critical patent/FR17C0003I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • External Artificial Organs (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR17C0003C 2001-03-12 2017-06-07 Steroides comme agonistes de fxr Active FR17C0003I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27495901P 2001-03-12 2001-03-12
PCT/EP2002/001832 WO2002072598A1 (fr) 2001-03-12 2002-02-21 Steroides comme agonistes de fxr

Publications (2)

Publication Number Publication Date
FR17C0003I1 true FR17C0003I1 (fr) 2017-07-21
FR17C0003I2 FR17C0003I2 (fr) 2018-05-25

Family

ID=23050302

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C0003C Active FR17C0003I2 (fr) 2001-03-12 2017-06-07 Steroides comme agonistes de fxr

Country Status (16)

Country Link
US (9) USRE48286E1 (fr)
EP (1) EP1392714B1 (fr)
JP (2) JP4021327B2 (fr)
AT (1) ATE303399T1 (fr)
AU (1) AU2002308295B2 (fr)
BE (1) BE2017C018I2 (fr)
CA (1) CA2440680C (fr)
CY (1) CY2017020I1 (fr)
DE (1) DE60205891T2 (fr)
DK (1) DK1392714T3 (fr)
ES (1) ES2248581T3 (fr)
FR (1) FR17C0003I2 (fr)
IL (2) IL157816A0 (fr)
NL (1) NL300877I2 (fr)
NO (2) NO326134B1 (fr)
WO (1) WO2002072598A1 (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
US6987121B2 (en) * 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
ITMI20021532A1 (it) * 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
EP2712617B2 (fr) 2004-03-12 2020-11-18 Intercept Pharmaceuticals, Inc. Traitement De La Fibrose Au Moyen De Ligands De Fxr
JPWO2005092328A1 (ja) * 2004-03-29 2008-02-07 財団法人ヒューマンサイエンス振興財団 Ｆｘｒ活性化化合物
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US7618956B2 (en) 2005-05-31 2009-11-17 The Gillette Company Reduction of hair growth
DK2040713T3 (da) * 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
KR100846441B1 (ko) * 2006-12-22 2008-07-16 재단법인서울대학교산학협력재단 스테롤 계 유도체를 함유하는 약제학적 조성물, 건강식품조성물, 화장품 조성물 및 파나소이드 엑스 핵 수용체 활성억제제 조성물
JP5292310B2 (ja) 2007-01-19 2013-09-18 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５調節剤としての２３−置換胆汁酸およびその使用方法
US8338628B2 (en) * 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
CN105037476B (zh) 2008-07-30 2018-06-12 英特塞普特医药品公司 Tgr5调节剂及其使用方法
HUE039171T2 (hu) 2008-11-19 2018-12-28 Intercept Pharmaceuticals Inc TGR5 modulátorok és azok alkalmazási eljárása
US20110257139A1 (en) 2008-12-19 2011-10-20 Royal College Of Surgeons In Ireland Treatment of diarrhoea
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CA3028207A1 (fr) * 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, utilisations et formes solides d'acide obeticholique
ES2655034T3 (es) 2012-10-26 2018-02-16 Intercept Pharmaceuticals, Inc. Proceso para preparar derivados del ácido biliar
AU2013352288B2 (en) * 2012-11-28 2017-11-23 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
AU2014278833A1 (en) 2013-06-13 2016-01-07 Fast Forward Pharmaceuticals B.V. CD40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
BR112016005507B1 (pt) 2013-09-11 2023-02-07 Centre National De La Recherche Scientifique (Cnrs) Uso de um agonista do receptor farnesoide x (fxr)
JP6621409B2 (ja) 2013-11-22 2019-12-18 ミナ セラピューティクス リミテッド Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物
CN104876995B (zh) * 2014-02-27 2016-09-07 人福医药集团股份公司 鹅去氧胆酸衍生物的制备方法
SI3626725T1 (sl) 2014-05-29 2023-04-28 Bar Pharmaceuticals S.R.L. Derivati holana za uporabo pri zdravljenju in/ali preprečevanju bolezni, posredovanih s FXR in TGR5/GPBAR1
EP3006557A1 (fr) 2014-10-07 2016-04-13 Heinrich-Heine-Universität Düsseldorf Acides biliaires pour induire la différenciation hépatique
CN105585603B (zh) * 2014-10-21 2019-05-24 重庆医药工业研究院有限责任公司 一种制备奥贝胆酸中间体的方法
MX2017005935A (es) 2014-11-06 2018-01-11 Enanta Pharm Inc Análogos de ácido biliar como agonistas fxr/tgr5 y métodos de uso de los mismos.
CN105669811B (zh) * 2014-11-17 2020-09-04 正大天晴药业集团股份有限公司 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途
CA2968309A1 (fr) 2014-11-19 2016-05-26 NZP UK Limited Steroides 6-alkyl-7-hydroxy-4-en-3-one utilises en tant qu'intermediaires pour la production de modulateurs de fxr steroidiens
WO2016079520A1 (fr) 2014-11-19 2016-05-26 Dextra Laboratories Limited Stéroïdes 6.alpha.-alkyl-6,7-dione utilisés en tant qu'intermédiaires pour la production de modulateurs de fxr stéroïdiens
CA2968301C (fr) 2014-11-19 2023-05-16 NZP UK Limited Steroides 5.beta.-6-alkyl-7-hydroxy-3-one utilises en tant qu'intermediaires pour la production de modulateurs de fxr steroidiens
TWI686401B (zh) 2014-11-19 2020-03-01 英商Ｎｚｐ英國有限公司 化合物（三）
CA2968404A1 (fr) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Analogues de l'acide biliaire utilises comme agonistes de fxr/tgr5 et leurs procedes d'utilisation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086115A1 (fr) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Dérivés de tétrazole d'acides biliaires utilisés en tant qu'agonistes de fxr/tgr5 et leurs procédés d'utilisation
CN105801653B (zh) 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CN104672290B (zh) * 2015-01-05 2017-06-06 北京普禄德医药科技有限公司 一种用于预防或治疗fxr‑介导的疾病的药物及其制备方法和用途
AR103624A1 (es) 2015-02-06 2017-05-24 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia de combinación
US10246483B2 (en) 2015-02-11 2019-04-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
CA2981503C (fr) 2015-03-31 2023-09-19 Enanta Pharmaceuticals, Inc. Derives d'acide biliaire utilises comme agonistes de fxr/tgr5 et leurs procedes d'utilisation
KR20170132879A (ko) 2015-04-07 2017-12-04 인터셉트 파마슈티컬즈, 인크. 조합 요법을 위한 약제학적 조성물
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN106290594B (zh) * 2015-05-27 2020-07-17 中美华世通生物医药科技（武汉）有限公司 测定奥贝胆酸片溶出含量的方法
CZ2015504A3 (cs) 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
CN106478759A (zh) * 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
WO2017053428A1 (fr) 2015-09-21 2017-03-30 Intercept Pharmaceuticals, Inc. Procédés pour favoriser la régénération hépatique
MX2018003649A (es) 2015-09-24 2018-05-11 Intercept Pharmaceuticals Inc Metodos e intermedios para la preparacion de derivados de acido biliar.
CN106589039B (zh) * 2015-10-15 2019-12-17 苏州朗科生物技术股份有限公司 一种奥贝胆酸的制备方法及相关化合物
CN106632564B (zh) * 2015-10-30 2021-04-13 苏州泽璟生物制药股份有限公司 奥贝胆酸盐及其无定形物和药物组合物
JP6749406B2 (ja) * 2015-11-06 2020-09-02 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸およびその誘導体の調製方法
CN106749466B (zh) * 2015-11-23 2019-05-21 南京济群医药科技股份有限公司 一种高纯度奥贝胆酸的制备方法
CN106854229A (zh) * 2015-12-08 2017-06-16 陈剑 一类脂肪酸盐,其制备及其在医药上的应用
WO2017115324A1 (fr) 2016-01-01 2017-07-06 Lupin Limited Formes solides d'acide obéticholique et procédés associés
MY196292A (en) * 2016-01-28 2023-03-24 Chia Tai Tianqing Pharmaceutical Group Co Ltd Steroid Derivative Fxr Agonist
EP3414256B1 (fr) * 2016-02-10 2022-01-19 Dr. Reddy's Laboratories Limited Procédé de purification utilisant sel d'amine de l'acide obéticholique
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
CN109467585A (zh) * 2016-03-11 2019-03-15 深圳市塔吉瑞生物医药有限公司 用于预防或治疗fxr-介导疾病的胆烷酸化合物
CN107188917A (zh) * 2016-03-15 2017-09-22 正大天晴药业集团股份有限公司 奥贝胆酸盐及其药物组合物
CN105541953B (zh) * 2016-03-15 2017-11-21 成都市新功生物科技有限公司 一种高纯度奥贝胆酸的重结晶纯化方法
EA037330B1 (ru) 2016-03-28 2021-03-12 Интерсепт Фармасьютикалз, Инк. Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
US11413295B2 (en) 2016-03-31 2022-08-16 Intercept Pharmaceuticals, Inc. Oral preparation of obeticholic acid
WO2017170854A1 (fr) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 Comprimé enrobé d'un film et présentant une stabilité chimique élevée de son principe actif
EP3228306A1 (fr) 2016-04-04 2017-10-11 ratiopharm GmbH Composé complexe comprenant un acide obéticholique et de la cyclodextrine et formulation pharmaceutique comprenant le composé complexe
WO2017174515A1 (fr) 2016-04-04 2017-10-12 Dipharma Francis S.R.L. Procédé de préparation d'un agoniste du récepteur farnésoïde x
ITUA20162272A1 (it) * 2016-04-04 2017-10-04 Dipharma Francis Srl Procedimento per la preparazione di un agonista del recettore farnesoide x
KR102377338B1 (ko) 2016-04-13 2022-03-21 인터셉트 파마슈티컬즈, 인크. 암의 치료 방법
TW201738254A (zh) 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
EA038580B9 (ru) * 2016-05-18 2021-10-05 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Агонист fxr, представляющий собой производное стероидов
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
WO2017207648A1 (fr) 2016-05-31 2017-12-07 Bionice, S.L.U Procédés et intermédiaires pour la préparation d'acide obéticholique et de dérivés de celui-ci
US10875887B2 (en) 2016-06-01 2020-12-29 Dr. Reddy's Laboratories Limited. Process for preparation of obeticholic acid
CZ2016385A3 (cs) 2016-06-28 2018-01-10 Zentiva, K.S. Způsoby přípravy intermediátů pro syntézu Obeticholové kyseliny
TWI606565B (zh) * 2016-08-31 2017-11-21 金寶電子工業股份有限公司 封裝結構及其製作方法
EP3293196A1 (fr) 2016-09-09 2018-03-14 Hexal AG Procédé de purification d'acide obéticholique
KR20190056436A (ko) 2016-10-04 2019-05-24 이난타 파마슈티칼스, 인코포레이티드 Fxr 작용제로서의 이속사졸 유사체 및 그의 사용 방법
EP3305799A3 (fr) 2016-10-07 2018-06-20 Lupin Limited Sels d'acide obéticholique
ES2918698T3 (es) 2016-11-29 2022-07-19 Enanta Pharm Inc Proceso para la preparación de derivados del ácido biliar de las sulfonilureas
CN108264532B (zh) * 2016-12-30 2021-02-26 上海现代制药股份有限公司 一种奥贝胆酸的制备方法及其中间体
WO2018152171A1 (fr) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Dérivés d'acide biliaire utilisés comme agonistes de fxr et leurs procédés d'utilisation
WO2018153933A1 (fr) 2017-02-21 2018-08-30 Genfit Combinaison d'un agoniste ppar avec un agoniste fxr
CN110944635A (zh) 2017-03-30 2020-03-31 国家医疗保健研究所 用于减少附加体病毒的持久性和表达的方法和药物组合物
WO2018187804A1 (fr) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Procédé de préparation de dérivés sulfonylcarbamate d'acides biliaires
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
CN109134572A (zh) * 2017-06-19 2019-01-04 中国科学院上海药物研究所 胆酸衍生物及其制备方法和用途
US11189472B2 (en) * 2017-07-17 2021-11-30 Applied Materials, Inc. Cathode assembly having a dual position magnetron and centrally fed coolant
EP3431486A1 (fr) 2017-07-18 2019-01-23 Bionice, S.L.U. Procédé et intermédiaires de synthèse de l'acide obéticholique et leurs dérivés
AU2018330495A1 (en) 2017-09-08 2020-03-26 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
US10611793B1 (en) 2017-11-27 2020-04-07 Teva Czech Industries S.R.O. Solid state forms of obeticholic acid salts
WO2019106043A1 (fr) 2017-11-29 2019-06-06 Hexal Ag Composition pharmaceutique comprenant de l'acide obéticholique
WO2019118571A1 (fr) * 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Analogues de l'isoxazole utilisés en tant qu'agonistes de fxr et leurs procédés d'utilisation
WO2019160813A1 (fr) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole en tant qu'agonistes de fxr et leurs procédés d'utilisation
ES2779985B2 (es) 2019-02-20 2021-03-04 Moehs Iberica Sl Sal de dietilamina del ácido 3alfa-tetrahidropiraniloxi-6alfa-etil-7alfa-hidroxi-5ß-colánico
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US20210261599A1 (en) 2018-08-24 2021-08-26 Solara Active Pharma Sciences Limited Process for the Preparation of Obeticholic Acid and Intermediates Used In the Process Thereof
CN111718388A (zh) 2019-03-19 2020-09-29 苏州泽璟生物制药股份有限公司 鹅去氧胆酸衍生物的制备方法
CN110025591A (zh) * 2019-04-29 2019-07-19 郑州泰丰制药有限公司 一种奥贝胆酸自乳化制剂及其软胶囊
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
SG11202113155XA (en) 2019-05-30 2021-12-30 Intercept Pharmaceuticals Inc Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
AU2020312735A1 (en) 2019-07-18 2021-12-16 Enyo Pharma Method for decreasing adverse-effects of interferon
AU2021207253A1 (en) 2020-01-15 2022-06-09 Centre National De La Recherche Scientifique Use of FXR agonists for treating an infection by hepatitis D virus
CN112341516B (zh) * 2020-11-14 2022-07-15 湖南科瑞生物制药股份有限公司 5,6-环氧类固醇类化合物及其制备方法和应用
WO2022152770A1 (fr) 2021-01-14 2022-07-21 Enyo Pharma Effet synergique d'un agoniste de fxr et d'ifn pour le traitement d'une infection par le virus de l'hépatite b
WO2022229302A1 (fr) 2021-04-28 2022-11-03 Enyo Pharma Potentialisation forte d'effets d'agonistes de tlr3 à l'aide d'agonistes de fxr en tant que traitement combiné

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2615902A (en) 1950-10-24 1952-10-28 Merck & Co Inc Chemical compounds and processes for preparing the same
US3859437A (en) 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
US4072695A (en) 1972-09-21 1978-02-07 Intellectual Property Development Corporation 3α,7α-Dihydroxy-cholanic acid derivatives
FR2444048B1 (fr) 1978-12-15 1981-08-14 Roussel Uclaf
FR2457302A1 (fr) 1979-05-23 1980-12-19 Roussel Uclaf Nouveau procede de purification de l'acide ursodesoxycholique
IT1165252B (it) 1979-07-12 1987-04-22 Blasinachim Spa Procedimento di purificazione dell'acido ursodesossicolico attraverso nuovi derivati
DE3003607C2 (de) 1980-02-01 1984-01-05 Dr.-Ing. Rudolf Hell Gmbh, 2300 Kiel Schaltungsanordnung zur partiellen Nachkorrektur von Farberkennungsräumen bei der Farberkennung
IT1137459B (it) 1981-04-14 1986-09-10 Erregierre Spa Prodesso per la preparazione di acido ursodeossicolico ad alta purezza
EP0101554B1 (fr) 1982-07-29 1986-10-15 Lehner A.G. Dérivés d'acides biliaires, leur procédé de préparation et compositions pharmaceutiques les contenant
IT1206112B (it) 1983-04-29 1989-04-14 Lehner Ag Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1212835B (it) 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
US4721709A (en) 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4892868A (en) 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1196377B (it) 1984-12-21 1988-11-16 Lehner Ag Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1223313B (it) * 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5175320A (en) * 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IT1229570B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
US4982868A (en) * 1989-11-07 1991-01-08 Robbins Edward S Iii Bail type pitcher for thin walled container
ES2074113T3 (es) * 1989-12-13 1995-09-01 Mitsubishi Chem Corp Nuevos derivados de acido pirazolil acrilico, utiles como fungicidas sistemicos para la proteccion de plantas y materiales.
JPH04250093A (ja) 1991-01-18 1992-09-04 Kanzaki Paper Mfg Co Ltd 感熱記録体
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CA2260044A1 (fr) 1996-07-12 1998-01-22 Stephen Alistair Smith Nouveau traitement contre la resistance a la leptine
US6060465A (en) 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
US6200995B1 (en) 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
AU754278B2 (en) * 1998-03-26 2002-11-07 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibody against human telomerase catalytic subunit
JP2002528721A (ja) 1998-10-23 2002-09-03 グラクソ グループ リミテッド 核内受容体のリガンド用のアッセイ
ATE326014T1 (de) 1998-11-09 2006-06-15 Atherogenics Inc Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
DE69940958D1 (de) 1998-12-23 2009-07-16 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
EP1473042B1 (fr) 1999-03-26 2006-06-21 City of Hope Criblage de composés modulant l'activité des récepteurs FXR
CA2368234A1 (fr) 1999-03-26 2000-10-05 City Of Hope Procede d'affectation du catabolisme du cholesterol au moyen d'un recepteur d'acide bilaire nucleaire
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
US6906057B1 (en) 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity
BR0011743A (pt) 1999-06-11 2002-03-05 Allergan Sales Inc Método para modular a atividade de receptor de fxr
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1284728A4 (fr) 1999-10-22 2004-05-19 Merck & Co Inc Medicaments destines au traitement de l'obesite
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2001288623A1 (en) * 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
US20020119958A1 (en) 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
WO2002084286A1 (fr) 2001-04-12 2002-10-24 Takeda Chemical Industries, Ltd. Procede de criblage
EP1285914B1 (fr) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Ligands du récepteur nucéaire nr1h4
EP1423113A4 (fr) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag Composes de liaison au recepteur nucleaire nr1h4
US20070010562A1 (en) 2001-08-13 2007-01-11 Ulrike Bauer Nr1h4 nuclear receptor binding compounds
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030144360A1 (en) 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
WO2003080803A2 (fr) 2002-03-21 2003-10-02 Smithkline Beecham Corporation Procedes d'utilisation d'agonistes du recepteur farnesoide x (fxr)
CA2482195A1 (fr) 2002-04-12 2003-10-23 The University Of Chicago Agonistes de recepteur active frx (farnesoid x receptor)
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
EP1562915A1 (fr) 2002-11-22 2005-08-17 SmithKline Beecham Corporation Agonistes de recepteur farnesoide x
US6993380B1 (en) 2003-06-04 2006-01-31 Cleveland Medical Devices, Inc. Quantitative sleep analysis method and system
WO2005032549A1 (fr) 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions et procedes pour traiter une fibrose
EP1568706A1 (fr) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Nouveau agonist steroidal pour FXR
TW200603818A (en) 2004-03-11 2006-02-01 Fresenius Kabi De Gmbh Conjugates of hydroxyethyl starch and erythropoietin
EP2712617B2 (fr) 2004-03-12 2020-11-18 Intercept Pharmaceuticals, Inc. Traitement De La Fibrose Au Moyen De Ligands De Fxr
US20060252670A1 (en) 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
BRPI0707794A2 (pt) 2006-02-14 2011-05-10 Intercept Pharmaceuticals Inc compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos
DK2040713T3 (da) 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
WO2008062475A2 (fr) 2006-10-26 2008-05-29 Cadila Healthcare Limited Compositions pharmaceutiques d'ursodiol
EP1947108A1 (fr) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. Modulateurs TGR5 et procédés d'utilisation correspondants
JP5292310B2 (ja) 2007-01-19 2013-09-18 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５調節剤としての２３−置換胆汁酸およびその使用方法
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
HUE039171T2 (hu) 2008-11-19 2018-12-28 Intercept Pharmaceuticals Inc TGR5 modulátorok és azok alkalmazási eljárása
WO2010121323A1 (fr) 2009-04-24 2010-10-28 Iceutica Pty Ltd Procédé destiné à la production de poudres de nanoparticules et de microparticules à usage commercial
EP2468762A1 (fr) 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Synthèse optimisée d'acides biliaires purs, cristallins et non polymorphes avec une taille de particules définie
WO2013037482A1 (fr) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Agonistes du récepteur du farnésoïde x pour le traitement et la prévention du cancer
FR2981572B1 (fr) 2011-10-21 2018-01-19 Inopharm Limited Compositions pharmaceutiques d'acide ursodesoxycholique
CA3028207A1 (fr) 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, utilisations et formes solides d'acide obeticholique
UA118673C2 (uk) 2013-05-14 2019-02-25 Інтерсепт Фармасутікалз, Інк. Похідні 11-гідроксилу жовчних кислот та їх амінокислотні кон'югати як модулятори фарнезоїдного x-рецептора

Also Published As

Publication number Publication date
NO326134B1 (no) 2008-10-06
DE60205891T2 (de) 2006-06-22
US20170305961A1 (en) 2017-10-26
DK1392714T3 (da) 2006-01-09
NO2017022I2 (no) 2018-08-20
AU2002308295B2 (en) 2007-08-23
IL157816A0 (en) 2004-03-28
US20140024631A1 (en) 2014-01-23
US8377916B2 (en) 2013-02-19
CY2017020I2 (el) 2017-11-14
JP2007269815A (ja) 2007-10-18
JP2004519492A (ja) 2004-07-02
JP4021327B2 (ja) 2007-12-12
DE60205891D1 (de) 2005-10-06
US20050080064A1 (en) 2005-04-14
US20190300564A9 (en) 2019-10-03
US20160152657A1 (en) 2016-06-02
US8969330B2 (en) 2015-03-03
USRE48286E1 (en) 2020-10-27
US9732117B2 (en) 2017-08-15
US7138390B2 (en) 2006-11-21
ES2248581T3 (es) 2006-03-16
ATE303399T1 (de) 2005-09-15
FR17C0003I2 (fr) 2018-05-25
CA2440680A1 (fr) 2002-09-19
NL300877I2 (nl) 2017-06-22
BE2017C018I2 (fr) 2021-02-04
US10421772B2 (en) 2019-09-24
NO20034011L (no) 2003-11-12
CA2440680C (fr) 2010-06-01
US20100022498A1 (en) 2010-01-28
US7786102B2 (en) 2010-08-31
NO20034011D0 (no) 2003-09-11
WO2002072598A1 (fr) 2002-09-19
US20150166598A1 (en) 2015-06-18
IL157816A (en) 2009-05-04
US20070142340A1 (en) 2007-06-21
EP1392714A1 (fr) 2004-03-03
NO2017022I1 (no) 2017-05-26
US8058267B2 (en) 2011-11-15
CY2017020I1 (el) 2017-11-14
EP1392714B1 (fr) 2005-08-31
US20120053163A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
FR17C0003I2 (fr) Steroides comme agonistes de fxr
WO2003006425A3 (fr) Nouveaux composes convenant comme anti-inflammatoires, immuno-modulateurs et anti-proliferants
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
WO2004007521A3 (fr) Composes chimiques
DE60121461D1 (de) Kondensierte pyridoindolderivate
ES2243579T3 (es) Derivados de pirazolopirideno.
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
DE60031886D1 (de) Purinderivate
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
DK1250337T3 (da) Substituerede homopiperidinylbenzimidazol-analoger som fundus-relaksanter
AU2002248531A1 (en) Pyrazolopyriadine derivatives
MXPA03008248A (es) Agentes colorantes para fibras de queratina que contienen derivados de n-heteroarilmetil-m-fenilendiamina, asi como nuevos derivados de n-heteroarilmetil-m-fenilendiamina.
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
PT1347960E (pt) Processo para a preparacao de (+)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperidina
DE60204014D1 (de) Chlormethylierung von thiophene
GB0309440D0 (en) Quinolone derivatives
MY128457A (en) 2-aminocarbonyl-9h-purine derivatives
DE69915688D1 (de) Benzonaphtyridin-1,8 derivate
SE9902147D0 (sv) Nya föreningar och farmaceutiska kompositioner innehållande desamma